A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women aged 18 years to 80 years.
Diagnosis of Type 2 diabetes mellitlus (T2DM) with current glycosylated hemoglobin A1c (HbA1c) levels of ≤ 11% at Screening and on a stable antidiabetic medication regimen for at least 30 days prior to randomization.
Presence of ongoing pain due to DPN for at least 6 months.
Willing to discontinue protocol-specified prohibited pain medications for DPN throughout the duration of the study.
You may not be if
Painful neuropathies or painful conditions other than DPN that may confound evaluation of pain due to DPN during the study.
Subjects who have failed previously on pregabalin (at the recommended label dose and for adequate duration) due to lack of efficacy.
Subjects with any clinically significant medical or psychiatric conditions or clinically significant laboratory test abnormalities.
Pregnant women, lactating mothers, men with partners currently pregnant, women suspected of being pregnant, and women who wish to be pregnant during the course of the clinical study.
Clareo Health | A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
